Online Pharmacy Stirs Ranitidine Controversy With Petition To Halt Sales
Executive Summary
After its tests showed ranitidine forms a nitrosamine impurity that is a probable carcinogen, Valisure asks FDA to suspend sales of antacid products containing the API. In citizen petition firm, online pharmacy also advises FDA to publish regulations requiring independent chemical testing, verification of drugs.
You may also be interested in...
US Petition Claims Benzene Forms In Benzoyl Peroxide, Requests Market Removal Of Acne Drugs
Valisure recommends FDA request recall and halt sales of products containing benzoyl peroxide due to its propensity to form the benzene. Products include numerous OTC monograph topical formulations as well Rx drugs with an acne indication available through approved applications.
GSK Agreed To Settle California Zantac Litigation After Judge Cleared Plaintiff's Experts To Testify
State court judge would've allowed testimony from 13 of 14 witnesses plaintiff proposed as experts for trial scheduled to start in late July. Plaintiff’s attorneys said decision on experts “signals significant litigation on the horizon for GSK.”
Ranitidine Cancer Risk Found Only By Litigation Plaintiffs’ ‘Unreliable’ Research, Judge Rules
Plaintiffs in Multi-District Litigation didn’t provide scientific evidence of OTC heartburn drug Zantac increasing risk of cancer. Federal judge says plaintiffs' research showed “a lack of substantiation for analytical leaps” in alleging dangerously high levels of NDMA in ranitidine drugs.